摘要
目的观察和评价FOLFIRI方案治疗无法手术切除的结直肠癌肝转移患者的临床疗效和毒副反应。方法32例结直肠癌肝转移患者采用FOLFIRI方案化疗，即伊立替康180mg／m2，静脉滴注90min，dl；CF200mg／m2，静脉滴注2h，dl；5．Fu400mg／m2，静脉推注，dl；5-Fu2400mg／m2，持续静注（CIV），46h，14d为1周期，2周期为1疗程。治疗2疗程以上评价每例患者的疗效与毒副反应。结果全组患者CR0例，PR13例，SD11例，PD8例，有效率40．6％。中位生存期16mo，TTP9mo。主要毒副反应为乙酰胆碱综合征、迟发性腹泻、中性粒细胞减少和口腔黏膜炎。结论FOLFIRI方案治疗结直肠癌肝转移，疗效令人鼓舞，毒副作用可耐受，是治疗结直肠癌肝转移较为理想的化疗方案之一。
Objective To evaluate the efficacy and toxicity of FOLFIRI regimen on Colorectal cancer patients with liver metastasis. Methods Thirty-two colorectal cancer patients with liver metastasis were treated by FOLFIRI regimen. FOLFIRI regimen consisted of irinotecanl80mg/mz, ivgtt, 90minutes, dl; Calcium folinate （CF） 200rag/mE, ivgtt, 2h, d1; 5-fluorouracil （5-FU） 400mg/m2, iv, d l; 5-fluorouracit （5-FU） 2400mg/m2,civ,46h, repeated every 2 weeks. The clinical efficacy and toxicity were evaluated after 8 weeks （two cycles） . Results The objective response rate for al~ patients was 40.6%, with 0 cases of CR, 13 PR, 11 SD, and 8 PD. The median survival time was 16 months, the time to progress （TTP） was 9 months. Acetylcholine syndrome, delayed diarrhea, myelosuppression and oral mucositis were major toxicity. Conclusions FOLFIRI regimen can be used in treating colorectal cancer with liver metastasis for its efficacy and tolerable toxicity.
出处
《世界肿瘤杂志》
2010年第1期33-35,42,共4页
Tumour Journal of the World
